AstraZeneca, the pharmaceutical giant, has reached a historic milestone by becoming the first UK-listed company to achieve a market capitalisation of £200 billion. This landmark achievement comes after a 1.1% increase in its share price, solidifying its position as the most valuable company in London.
This success story is a testament to CEO Pascal Soriot's leadership, who successfully resisted a takeover bid from Pfizer in 2014 and steered AstraZeneca towards impressive growth. Under Soriot, the company has focused on revamping its drugs pipeline and developing a strong portfolio in various therapeutic areas, including cancer, cardiovascular, and rare diseases.
The company has already achieved Soriot's ambitious target of boosting revenues to $45 billion, and now aims to nearly double that figure to $80 billion by 2030.
